R&D News | pharmaphorum

News

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –

News

Eiger wields axe as FDA sets high bar for hepatitis drug

Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud

News

Biomarker study raises hope of better depression therapies

Researchers may have identified imaging-based biomarkers that could be used to identify different subtypes of major depressive disorder (MDD) and potentially lead to the d

News

Gates Foundation, Wellcome put $550m behind new TB jab

A potentially game-changing new vaccine for tuberculosis is set for a major clinical trials programme, thanks to $550 million in funding from philanthropic organisations t

News

Sanofi sets out plan to lead the RSV vaccine market

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a

News

AbbVie, Genmab eye label expansion for Epkinly

Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

Eiger wields axe as FDA sets high bar for hepatitis drug

Biomarker study raises hope of better depression therapies

Gates Foundation, Wellcome put $550m behind new TB jab

Sanofi sets out plan to lead the RSV vaccine market

AbbVie, Genmab eye label expansion for Epkinly

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks